ClinicalTrials.gg
CompletedNCT01615796Updated May 9, 2017

Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses

A Phase 1 interventional study of Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined and Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined in Infections, Respiratory Tract, sponsored by GlaxoSmithKline. Completed at 1 site in Australia. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-09.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Respiratory Tract Infections by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Respiratory Tract Infections · GlaxoSmithKline.

Enrollment
4th of 19
86 · median 46
Started
2012
with 2 others
Phase 1
14 of 21
none open now
Registered
7th of 21
by date

Among the 21 studies in Respiratory Tract Infections by GlaxoSmithKline, this one is the 4th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2012, is one of 14 in phase 1, and was the 7th registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

None of the 21 studies in Respiratory Tract Infections by GlaxoSmithKline is open now. The open studies under Respiratory Tract Infections, anywhere →

Who these studies take

Of the 74 Respiratory Tract Infections studies recruiting now, 35 (47%) set no upper age limit and 31 (42%) stop at 75 or younger; 34 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in Respiratory Tract Infections by GlaxoSmithKline as a file.
02

Study summary

GSK2140944 belongs to the Bacterial Type II Topoisomerase Inhibitor (BTI) class of antibiotics. GSK2140944 has demonstrated in vitro and in vivo activity against Gram positive pathogens including methicillin resistant Staphylococcus aureus (MRSA) and Gram-negative pathogens associated with respiratory tract, skin and soft tissue infections including isolates resistant to existing classes of antimicrobials.

Read the detailed description

GSK2140944 belongs to the Bacterial Type II Topoisomerase Inhibitor (BTI) class of antibiotics. GSK2140944 has demonstrated in vitro and in vivo activity against Gram positive pathogens including methicillin resistant Staphylococcus aureus (MRSA) and Gram-negative pathogens associated with respiratory tract, skin and soft issue infections including isolates resistant to existing classes of antimicrobials. This study will be the first administration of GSK2140944 as an intravenous (IV) formulation in humans and will be conducted in two (2) parts. Single IV doses will be explored in Part A and repeat IV doses will be explored in Part B. In addition, this study will evaluate the absolute bioavailability of an oral capsule formulation as compared to the IV formulation in Part A. Both study parts will investigate the safety, tolerability and pharmacokinetic profile of GSK2140944 in healthy adult subjects.

03

Conditions studied

  • Infections, Respiratory Tract

Keywords

  • GSK2140944
  • antibiotics
  • first time in human
  • pharmacokinetics
  • intravenous
  • safety
  • absolute bioavailability
  • Bacterial Type II
  • tolerability
  • infection
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • , ALT, alkaline phosphatase and less than and equal to 1.5xULN (isolated bilirubin less than 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin less than 35%).
  • Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • Male or female between 18 and 60 years of age inclusive, at the time of signing the .
  • A female subject is eligible to participate if she is of: Non- defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or defined as 12 months of spontaneous amenorrhea. To confirm post-menopausal status, a blood sample for simultaneous follicle stimulating hormone (FSH) greater than 40 MlU/ml and estradiol less than 40 pg/ml (less than 147 pmol/L) is confirmatory. Male subjects with female partners of child-bearing potential must agree to use one of the methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until the final follow-up visit.
  • Body weight greater than and equal to 50 kg and within the range 19 - 31 kg/m2 (inclusive).
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form

Exclusion criteria

Exclusion Criteria:

  • A positive pre-study surface antigen or positive antibody result within 3 months of screening or positive (HIV) antibody.
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • Any central nervous system (e.g., seizures), cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal conditions or history of such conditions that, in the opinion of the investigator may place the subject at an unacceptable risk as a participant in this trial or may interfere with the absorption, distribution, metabolism or excretion of drugs.
  • A positive urine test for drugs of abuse or alcohol (or alcohol breath test) at screening.
  • A screening urinalysis positive for protein or glucose (greater than "trace" findings of protein or glucose).
  • A serum creatinine value between screening and Day -1 visit that is increased by more than 0.2 mg/dL (or 15.25 umol/L) changes.
  • History of photosensitivity to quinolones.
  • Unwillingness to commit to avoid excessive exposure to sunlight (or exposure whilst on a tanning bed) which would cause a sunburn reaction from first dose up to and including the follow-up visit.
  • History of drug abuse within 6 months of the study.
  • History of smoking or use of nicotine containing products within 3 months of screening, or a positive urine cotinine indicative of smoking at screening.
  • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of greater than 21 units (or an average daily intake of greater than 3 units) for males or an average weekly intake of greater than 14 units (or an average daily intake greater than 2 units) for females. One unit is equivalent to 270 mL of full strength beer, 470 mL of light beer, 30 mL of spirits and 100 mL of wine.
  • The subject has participated in a clinical trial and has received a drug or a new chemical entity within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of current study medication.
  • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication, or use of St. John's Wort within 14 days prior to the first dose of study medication. By exception, the volunteer may take paracetamol or acetaminophen (less than and equal to 2 grams/day) up to 48 hours prior to the first dose of study medication. However, the Investigator and GSK study team can review medication on a case by case basis to determine if its use would compromise subject safety or interfere with the study procedures or data interpretation.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  • Donation of blood in excess of 500 mL within 12 weeks prior to dosing.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • History of tendon rupture.
  • Subject is mentally or legally incapacitated.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia (if the clinical research unit uses heparin to maintain intravenous cannula patency).
  • Consumption of red wine, seville oranges, grapefruit or grapefruit juice, pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices containing such products from 7 days prior to the first dose of study medication.
  • Exclusion criteria for screening (a single repeat is allowed for eligibility determination): Heart rate: Males - less than 40 and greater than 100 bpm; Females: less than 50 and greater than 100 bpm; PR Interval: Males and Females - less than 120 and greater than 220 msec; QRS duration: Males and Females - less than 70 and greater than 100 msec; or QTcF interval: Males and Females - greater than 450 msec; Evidence of previous myocardial infarction (does not include ST segment changes associated with repolarization); Subject has Bundle Branch Block; Any conduction abnormality (including but not specific to left or right complete bundle branch block, AV block [2nd degree or higher], Wolf Parkinson White [WPW] syndrome), sinus pauses greater than 3 seconds, non-sustained or sustained ventricular tachycardia (greater than and equal to 3 consecutive ventricular ectopic beats) or any significant arrhythmia which, in the opinion of the principal investigator and GSK medical monitor, will interfere with the safety of the individual subject.
  • Screening holter monitoring shows one or more of the following: Any symptomatic arrhythmia (except isolated extra systoles); Sustained cardiac arrhythmias (such as atrial fibrillation or flutter, SVT (greater than 10 consecutive beats)); Sinus tachycardia (or supraventricular tachycardia) greater than 150 bpm; Non-sustained or sustained ventricular tachycardia (defined as greater than and equal to 3 consecutive ventricular ectopic beats); Any conduction abnormality (including but not specific to left or right complete bundle branch block, AV block [2nd degree or higher in an awake subject], WPW syndrome, other pre-excitation syndromes); Symptomatic sinus pause or sinus pause >3 seconds - unless patient is straining, vomiting, or having some other type of hypervagal response; 300 or more supraventricular ectopic beats in 24 hours; 250 or more ventricular ectopic beats in 24 hours; Ischemia, diagnosed by a sequence of EKG changes that include flat or downsloping ST-segment depression greater than 0.1 mV, with a gradual onset and offset that lasts for a minimum period of 1 minute. Each episode of ischemia must be separated by a minimum duration of at least 1 minute, during which the ST segment returns back to baseline (1x1x1 rule).
  • \<2000 cells per microliter (a single repeat is allowed for eligibility determination).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Cohort A1

    GSK2140944 200mg single dose

    Drug: Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined

  • Experimental
    Cohort A2

    GSK2140944 600mg single dose

    Drug: Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined

  • Experimental
    Cohort A3

    GSK2140944 1200mg single dose

    Drug: Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined

  • Experimental
    Cohort A4

    GSK2140944 1800mg single dose

    Drug: Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined

  • Experimental
    Cohort A5

    GSK2140944 1800mg single dose

    Drug: Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined

  • Experimental
    Cohort A6

    GSK2140944 dose to be determined, single dose

    Drug: Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined

  • Experimental
    Cohort B1

    GSK2140944 400 mg repeat dose BID up to 7 days

    Drug: Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined

  • Experimental
    Cohort B2

    GSK2140944 750 mg repeat dose BID up to 7 days

    Drug: Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined

  • Experimental
    Cohort B3

    GSK2140944 1000 mg repeat dose BID up to 7 days

    Drug: Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined

  • Experimental
    Cohort B4

    GSK2140944 to be determined repeat dose BID up to 7 days

    Drug: Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined

  • Experimental
    Cohort B5

    GSK2140944 to be determined repeat dose TID up to 14 days

    Drug: Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined

  • Experimental
    Cohort B6

    GSK2140944 to be determined repeat dose TID up to 14 days

    Drug: Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined

Interventions

  • DrugPart A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined

    Subjects receive a single dose of GSK2140944

  • DrugPart B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined

    Subjects will receive repeat doses of GSK2140944 BID/TID for up to 14 Days

06

What researchers measure

Primary outcomes

  1. Composite of pharmacokinetic (PK) parameters of GSK2140944 including area under the curve following single dose administration.

    Measurements include area under the plasma concentration curve (AUC) from time zero (pre-dose) extrapolated to infinite time (AUC(0-infinity), AUC over the dosing interval AUC(0-tau). AUC (0-12) and AUC(0-24).

    Time frame: Part A up to 4 days

  2. Composite of PK parameters for GSK2140944 following single dose administration

    Measurements include maximum observed concentration (Cmax), systemic clearance of parent drug (CL). volume of distribution at steady state of parent drug after intravascular administration (Vdss), Mean residence time (MRT) and terminal phase half-life (t1/2)

    Time frame: Part A up to 4 Days

  3. Composite of PK parameters for GSK2140944 including area under the curve following repeat dose administration.

    Measurements include AUC from time zero (pre-dose) extrapolated to infinite time (AUC(0-infinity), AUC over the dosing interval AUC(0-tau). AUC (0-8), AUC (0-12) and AUC(0-24).

    Time frame: Part B Days 4, 7, 10 and 14

  4. Composite of PK parameters for GSK2140944 following repeat dose administration.

    Measurements include Cmax, CL. Vdss, MRT and t1/2.

    Time frame: Part B Days 4, 7, 10 and 14

  5. Composite of PK parameters for GSK2140944 following repeat dose administration including maximum concentration, area under the curve, accumulation ratio and clearance of parent drub.

    Measurements include AUC(0-tau). Cmax, pre-dose (trough) concentration at the end of the dosing interval (Cτ), accumulation ratio (Ro) and CL

    Time frame: Part B Days 4, 7, 10 and 14

  6. GSK2140944 safety parameters - adverse events

    Time frame: Part A change from baseline for 15 Days. Part B change from baseline for up to 28 Days

  7. GSK2140944 safety parameters - telemetry

    Time frame: Part A change from baseline for 15 Days. Part B change from baseline for up to 28 Days

  8. GSK2140944 safety parameters - absolute values and changes over time of hematology, clinical chemistry and urinalysis

    Time frame: Part A change from baseline for 15 Days. Part B change from baseline for up to 28 Days

  9. GSK2140944 safety parameters - vital signs (blood pressure, heart rate, temperature)

    Time frame: Part A change from baseline for 15 Days. Part B change from baseline for up to 28 Days

  10. GSK2140944 safety parameters - Electrocardiogram (ECG) measurements

    Time frame: Part A change from baseline for 15 Days. Part B change from baseline for up to 28 Days

Secondary outcomes

  1. A composite of pharmacokinetic parameters including dose proportionality following single and repeat doses of GSK2140944.

    GSK2140944 AUC(0-∞) and Cmax for single doses and AUC(0-τ) and Cmax for repeat doses.

    Time frame: 44 Days in Part A, 7, 10 and 14 Days in Part B

  2. A composite of pharmacokinetic urinary parameters to estimate the urinary excretion of unchanged GSK2140944 following a therapeutically relevant dose and higher single dose in healthy volunteers.

    The amount of unchanged GSK2140944 in urine (Ae), fraction of the dose excreted in urine (fe) and renal clearance (CLr).

    Time frame: 4 Days in Part A

  3. A composite of pharmacokinetic parameters to estimate the absolute bioavailability of the oral capsule formulation of GSK2140944 as compared to the IV formulation following single equivalent doses in healthy volunteers.

    Compare oral mean residence time (MRTpo), oral mean absorption time (MATpo) and absolute bioavailability of capsule formulation to IV formulation.

    Time frame: 4 Days in Part A

  4. A composite of pharmacokinetic parameters to examine the extent of accumulation and time invariance following repeat doses of GSK2140944.

    Measurements include Ro using AUC(0-τ) for repeat dose and AUC(0-12) for single dose, time invariance using repeat dose AUC(0-τ) and single dose AUC(0-∞)

    Time frame: 4, 7, 10 and 14 days in Part B

  5. A composite of pharmacokinetic parameters to examine achievement of steady-state following repeat doses of GSK2140944.

    Trough concentrations at the end of the dosing interval (Ctau) collected at pre-morning dose on Days 7 and 8 (together with pre-morning dose Ctau on Days 9 from the full PK profiles on Day 9) or Ctau collected at pre-morning dose on Days 10 and 11 (together with pre-morning dose Ctau on Day 12 from the full PK profiles on Day 12) or Ctau collected at pre-morning dose on Days 14 and 15 (together with pre-morning dose Ctau on Day 16 from the full PK profiles on Day 16) to assess achievement of steady-state.

    Time frame: 7, 10 and 14 days in Part B

07

Study locations

1 site
  • GSK Investigational Site
    Randwick, New South Wales 2031, Australia
08

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2012 to primary completion in Feb 2014, 20 months.

Of 26 industry-sponsored phase 1 interventional studies under Respiratory Tract Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 20 months is above that.

Counting every sponsor, half of 35 studies reached it within 8 months; a quarter within 1 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2012
First posted
Jun 11, 2012
StartActual
Jun 4, 2012
Primary completionActual
Feb 21, 2014
CompletionActual
Feb 21, 2014
Last update
May 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01615796
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 11, 2012
Start date
Jun 4, 2012
Primary completion
Feb 21, 2014
Completion
Feb 21, 2014
Last update
May 9, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion